The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

 
Web www.patentalert.com

< Pyrrolidine derivatives as factor Xa inhibitors

> Phenylamino isothiazole carboxamidines as MEK inhibitors

~ 00467